Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 9, 2017, Pages

  Platt, Lucy ^a   Minozzi, Silvia ^b   Reed, Jennifer ^c   Vickerman, Peter ^d   Hagan, Holly ^c   French, Clare ^d   Jordan, Ashly ^c   Degenhardt, Louisa ^e   Hope, Vivian ^f   Hutchinson, Sharon ^g   Maher, Lisa ^h   Palmateer, Norah ^g   Taylor, Avril ⁱ   Bruneau, Julie ^j   Hickman, Matthew ^d  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b DEPARTMENT OF EPIDEMIOLOGY   (Italy)

^c NEW YORK UNIVERSITY   (United States)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^g HEALTH PROTECTION SCOTLAND   (United Kingdom)

^h UNIVERSITY OF NEW SOUTH WALES   (Australia)

ⁱ UNIVERSITY OF THE WEST OF SCOTLAND   (United Kingdom)

^j UNIVERSITÉ DE MONTRÉAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE TRANSMISSION; EVIDENCE BASED MEDICINE; HEALTH PROGRAM; HEPATITIS C; HIGH RISK BEHAVIOR; HUMAN; INFECTION PREVENTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; META ANALYSIS; OPIATE SUBSTITUTION TREATMENT; OUTCOME ASSESSMENT; PATIENT PARTICIPATION; PRIORITY JOURNAL; PROGRAM DEVELOPMENT; PROGRAM EFFECTIVENESS; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT DURATION; COMPLICATION; FEMALE; MALE; PREVENTIVE HEALTH SERVICE; PROCEDURES; PROGRAM EVALUATION; SUBSTANCE ABUSE; TRANSMISSION;

FEMALE; HEPATITIS C; HUMANS; MALE; NEEDLE-EXCHANGE PROGRAMS; OPIATE SUBSTITUTION TREATMENT; PROGRAM EVALUATION; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 85029563949     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD012021.pub2     Document Type: Review

References (191)

1. Unpublished dataset [personal communication]. Email to: Paul Dietz 1st November 2016. 6703596
2. Unpublished dataset [personal communication]. Email to: Julie Bruneau 1st November 2016. 6703598
3. Craine N, Hickman M, Parry JV, Smith J, Walker AM, Russell D, et al. Incidence of hepatitis C in drug injectors: the role of homelessness, opiate substitution treatment, equipment sharing, and community size. Epidemiology and Infection 2009;137(9):1255-65. 6703600
4. Crofts N, Nigro L, Oman K, Stevenson E, Sherman J. Methadone maintenance and hepatitis C virus infection among injecting drug users. Addiction 1997;92(8):999-1005. 6703602
5. Hagan H, Des Jarlais DC, Friedman SR, Purchase D, Alter MJ. Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program. American Journal of Public Health 1995;85(11):1531-7. 6703604
6. Hagan H, McGough JP, Thiede H, Weiss NS, Hopkins S, Alexander ER. Syringe exchange and risk of infection with hepatitis B and C viruses. American Journal of Epidemiology 1999;149(3):203-13. 6703606
7. Holtzman D, Barry V, Ouellet LJ, Des Jarlais DC, Vlahov D, Golub ET, et al. The influence of needle exchange programs on injection risk behaviors and infection with hepatitis C virus among young injection drug users in select cities in the United States, 1994-2004. Preventive Medicine 2009;49(1):68-73. 6703608
8. Hope VD, Hickman M, Ngui SL, Jones S, Telfer M, Bizzarri M, et al. Measuring the incidence, prevalence and genetic relatedness of hepatitis C infections among a community recruited sample of injecting drug users, using dried blood spots. Journal of Viral Hepatitis 2011;18(4):262-70. 6703610
9. Unpublished dataset [personal communication]. Email to: Vivian Hope 1st November 2015. 6703612
10. Unpublished dataset [personal communication]. Email to: Ali Judd 1st November 2015. 6703614
11. Bruandet A, Lucidarme D, Decoster A, Ilef D, Harbonnier J, Jacob C, et al. Incidence and risk factors of HCV infection in a cohort of intravenous drug users in the North and East of France [Incidence et facteurs de risque de la seroconversion au virus de l'hepatite C dans une cohorte d'usagers de drogue intraveineux du nord-est de la France]. Revue d'Epidemiologie et de Sante Publique 2006;54(HS1):1S15-22. 6703616
12. Lucidarme D, Bruandet A, Ilef D, Harbonnier J, Jacob C, Decoster A, et al. Incidence and risk factors of HCV and HIV infections in a cohort of intravenous drug users in the North and East of France. Epidemiology and Infection 2004;132(4):699-708. 6703617
13. Unpublished dataset [pers comm]. Email to: Meghan Morris 1st November 2016. 6703619
14. Unpublished dataset [personal communication]. Email to: Shruti Mehta 1st November 2015. 6703621
15. Nolan S, Dias Lima V, Fairbairn N, Kerr T, Montaner J, Grebely J, et al. The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users. Addiction 2014;109(12):2053-9. 6703623
16. Unpublished dataset [personal communication]. Email to: Kimberly Page 1st November 2015. 6703625
17. Allen EJ, Palmateer NE, Hutchinson SJ, Cameron S, Goldberg DJ, Taylor A. Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in Scotland. International Journal on Drug Policy 2012;23(5):346-52. 6703627
18. Palmateer N, Taylor A, Goldberg DJ, Munro A, Aitken C, Shepherd SJ, et al. Risk of transmission associated with sharing drug injecting paraphernalia: Analysis of recent hepatitis C virus (HCV) infection using cross-sectional survey data. Journal of Viral Hepatitis 2014;21(1):25-32. 6703628
19. Palmateer NE, Taylor A, Goldberg DJ, Munro A, Aitken C, Shepherd SJ, et al. Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions. PLOS ONE 2014;9(8):e104515. 6703629
20. Patrick DM, Tyndall MW, Cornelisse PGA, Li K, Sherlock CH, Rekart ML, et al. Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. Canadian Medical Association Journal 2001;165(7):889-95. 6703631
21. Rezza G, Sagliocca L, Zaccarelli M, Nespoli M, Siconolfi M, Baldassarre C. Incidence rate and risk factors for HCV seroconversion among injecting drug users in an area with low HIV seroprevalence. Scandinavian Journal of Infectious Diseases 1996;28(1):27-9. 6703633
22. Roy E, Alary M, Morissette C, Leclerc P, Boudreau JF, Parent R, et al. High hepatitis C virus prevalence and incidence among Canadian intravenous drug users. International Journal of STD & AIDS 2007;18(1):23-7. 6703635
23. Ruan Y, Qin G, Yin L, Chen K, Qian H-Z, Hao C, et al. Incidence of HIV, hepatitis C and hepatitis B viruses among injection drug users in southwestern China: A 3-year follow-up study. AIDS 2007;21(Suppl 8):S39-46. 6703637
24. Spittal PM, Pearce ME, Chavoshi N, Christian WM, Moniruzzaman A, Teegee M, et al. The Cedar Project: high incidence of HCV infections in a longitudinal study of young Aboriginal people who use drugs in two Canadian cities. BMC Public Health 2012;12:632. 6703639
25. Thiede H, Hagan H, Murrill CS. Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area. Journal of Urban Health 2000;77(3):331-45. 6703641
26. Thorpe LE, Ouellet LJ, Hershow R, Bailey SL, Williams IT, Williamson J, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. American Journal of Epidemiology 2002;155(7):645-53. 6703643
27. Tsui JI, Evans JL, Lum PJ, Hahn JA, Page K. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. JAMA Internal Medicine 2014;174(12):1974-81. 6703645
28. Vallejo F, Barrio G, Brugal MT, Pulido J, Toro C, Sordo L, et al. High hepatitis C virus prevalence and incidence in a community cohort of young heroin injectors in a context of extensive harm reduction programmes. Journal of Epidemiology & Community Health 2015;69(6):599-603. 6703647
29. Van Beek I, Dwyer R, Dore G J, Luo K, Kaldor JM. Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study. BMJ 1998;317(7156):433-7. 6703649
30. Van Den Berg C, Smit C, Van Brussel G, Coutinho R, Prins M. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction 2007;102(9):1454-62. 6703651
31. White B, Dore GJ, Lloyd AR, Rawlinson WD, Maher L. Opioid substitution therapy protects against hepatitis C virus acquisition in people who inject drugs: the HITS-c study. Medical Journal of Australia 2014;201(6):326-9. 6703653
32. Aubisson S, Carrieri P, Lovell A-M, Ben Diane M-K, Peretti-Watel P, Spire B. New tools for preventing and evaluating risk practices for hepatitis C transmission among injection drug users: some reflections on injection rooms and the measurement of risk-taking behaviors [Quels nouveaux outils pour prevenir et evaluer les pratiques a risque chez les injecteurs de drogue face au VHC? Reflexions sur les salles d'injection et les outils de mesure des prises de risques]. Revue d'Epidemiologie et de Sante Publique 2006;54(Spec No 1):1S69-75. 6703655
33. Azim T, Hussein N, Kelly R. Effectiveness of harm reduction programmes for injecting drug users in Dhaka city. Harm Reduction Journal 2005;2:22. 6703657
34. Bayoumi AM, Zaric GS. The cost-effectiveness of Vancouver's supervised injection facility. CMAJ 2008;179:1143-51. 6703659
35. Burt RD, Hagan H, Garfein RS, Sabin K, Weinbaum C, Thiede H. Trends in hepatitis B virus, hepatitis C virus, and human immunodeficiency virus prevalence, risk behaviors, and preventive measures among Seattle injection drug users aged 18-30 years, 1994-2004. Urban Health 2007;84(3):436-54. 6703661
36. Buxton JA, Kuo ME, Ramji S, Yu A, Krajden M. Methadone use in relation to hepatitis C virus testing in British Columbia. Canadian Journal of Public Health. Revue Canadienne de Sante Publique 2010;101(6):491-4. 6703663
37. Collins R, Ewing D, Boggs B, Patterson D. Opiate substitution prescribing in Belfast - two year follow up study. Irish Journal of Psychological Medicine 2009;26(4):183-6. 6703665
38. Cox GM, Lawless MC, Cassin SP, Geoghegan TW. Syringe exchanges: a public health response to problem drug use. Irish Medical Journal 2000;93(5):143-6. 6703667
39. Crofts N, Hopper JL, Bowden DS, Breschkin AM, Milner R, Locarnini SA. Hepatitis C virus infection among a cohort of Victorian injecting drug users. Medical Journal of Australia 1993;159(4):237-41. 6703669
40. Des Jarlais DC, Perlis T, Arasteh K, Torian LV, Hagan H, Beatrice S, et al. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001. AIDS 2005;19:S20-5. 6703671
41. Des Jarlais DC, Arasteh K, Perlis T, Hagan H, Abdul-Quader A, Heckathorn DD, et al. Convergence of HIV seroprevalence among injecting and non-injecting drug users in New York City. AIDS 2007;21(2):231-5. 6703673
42. De Vos AS, Van Der Helm JJ, Prins M, Kretzschmar MEE. Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam: Evidence for harm reduction?. Journal of the International AIDS Society 2012;15:78. 6703675
43. Dubois-Arber F, Balthasar H, Huissoud T, Zobel F, Arnaud S, Samitca S, et al. Trends in drug consumption and risk of transmission of HIV and hepatitis C virus among injecting drug users in Switzerland, 1993-2006. Euro Surveillance: Bulletin Europeen sur les Maladies Transmissibles = European Communicable Disease Bulletin 2008;13:22. Erratum in: Euro Surveill. 2008 May 29;13(22). pii: 18887. 6703677
44. Emmanuelli J, Desenclos J-C. "Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003": Corrigendum. Addiction 2006;101(4):616. 6703679
45. Emmanuelli J, Desenclos J-C. Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003. Addiction 2005;100(11):1690-700. 6703680
46. Esteban J, Gimeno C, Aragones A, Barril J, de la Cruz Pellin M. Prevalence of infection by HIV and hepatitis C virus in a cohort of patients on methadone treatment [Prevalencia de infeccion por virus de la inmunodeficiencia humana y hepatitis C en una cohorte de pacientes en tratamiento de mantenimiento con metadona]. Medicina Clinica 2003;120(20):765-7. 6703682
47. Falster K, Kaldor JM, Maher L. Hepatitis C virus acquisition among injecting drug users: a cohort analysis of a national repeated cross-sectional survey of needle and syringe program attendees in Australia, 1995-2004. Urban Health 2009;86:106-18. 6703684
48. Fatseas M, Denis C, Serre F, Dubernet J, Daulouede JP, Auriacombe M. Change in HIV-HCV risk-taking behavior and seroprevalence among opiate users seeking treatment over an 11-year period and harm reduction policy. AIDS and Behavior 2012;16(7):2082-90. 6703686
49. Fhima A, Henrion R, Lowenstein W, Charpak Y. Two-year follow-up of an opioid-user cohort treated with high-dose buprenorphine (Subutex) [Suivi a 2 ans d'une cohorte de patients dependants aux opiaces traites par buprenorphine haut dosage (Subutex)]. Annales De Medecine Interne (Paris) 2001;152(Suppl 3):IS26-36. 6703688
50. Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. New England Journal of Medicine 2003;349(10):949-58. 6703690
51. Fuller CM, Ompad DC, Galea S, Wu Y, Koblin B, Vlahov D. Hepatitis C incidence--a comparison between injection and noninjection drug users in New York City. Journal of Urban Health 2004;81(1):20-4. 6703692
52. Galeazzl B, Tufano A, Barbierato E, Bortolotti F. Hepatitis C virus infection in Italian intravenous drug users: Epidemiological and clinical aspects. Liver 1995;15(4):209-12. 6703694
53. Gambashidze N, Sikharulidze Z, Piralishvili G, Gvakharia N. Evaluation of pilot methadone maintenance therapy in Georgia (Caucasus). Georgian Medical News 2008;N/A(160-1):25-30. 6703696
54. Garfein RS, Doherty MC, Monterroso ER, Thomas DL, Nelson KE, Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. Journal of Acquired Immune Deficiency Syndromes 1998;18(Suppl 1):S11-9. 6703698
55. Garfein RS, Golub ET, Greenberg AE, Hagan H, Hanson DL, Hudson SM, et al. A peer-education intervention to reduce injection risk behaviors for HIV and hepatitis C virus infection in young injection drug users. AIDS 2007;21(14):1923-32. 6703700
56. Garten RJ, Lai S, Zhang J, Liu W, Chen J, Vlahov D, et al. Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China. International Journal of Epidemiology 2004;33(1):182-8. 6703702
57. Gervasoni J-P, Balthasar H, Huissoud T, Jeannin A, Dubois-Arber F. A high proportion of users of low-threshold facilities with needle exchange programmes in Switzerland are currently on methadone treatment: Implications for new approaches in harm reduction and care. International Journal on Drug Policy 2012;23(1):33-6. 6703704
58. Goldberg D, Cameron S, McMenamin J. Hepatitis C virus antibody prevalence among injecting drug users in Glasgow has fallen but remains high. Communicable Disease and Public Health 1998;1(2):95-7. 6703706
59. Goldberg D, Burns S, Taylor A, Cameron S, Hargreaves D, Hutchinson S. Trends in HCV prevalence among injecting drug users in Glasgow and Edinburgh during the era of needle/syringe exchange. Scandinavian Journal of Infectious Diseases 2001;33(6):457-61. 6703708
60. Goswami P, Medhi GK, Armstrong G, Setia MS, Mathew S, Thongamba G, et al. An assessment of an HIV prevention intervention among People Who Inject Drugs in the states of Manipur and Nagaland, India. International Journal on Drug Policy 2014;25(5):853-64. 6703710
61. Grebely J, Bruggmann P, Backmund M, Dore G J. Prevention and management of hepatitis C virus infection among people who inject drugs: moving the agenda forward. International Symposium on Hepatitis in Substance Users, Brussels, Belgium, 15-16 September 2011. Clinical Infectious Diseases 2013;57:S29-S137. 6703712
62. Grebely J, Lima VD, Marshall BDL, Milloy M-J, DeBeck K, Montaner J, et al. Declining incidence of hepatitis C virus infection among people who inject drugs in a Canadian setting, 1996-2012. PLOS ONE 2014;9(6):e97726. [DOI: 10.1371/journal.pone.0097726]6703714
63. Guadagnino V, Zimatore G, Izzi A, Caroleo B, Rocca A, Montesano F, et al. Relevance of intravenous cocaine use in relation to prevalence of HIV, hepatitis B and C virus markers among intravenous drug abusers in southern Italy. Journal of Clinical & Laboratory Immunology 1995;47(1):1-9. 6703716
64. Hagan H, Mcgough JP, Thiede H, Hopkins SG, Weiss N S, Alexander ER. Volunteer bias in nonrandomized evaluations of the efficacy of needle-exchange programs. Journal of Urban Health-Bulletin of the New York Academy of Medicine 2000;77(1):103-12. 6703718
65. Heimer R. Syringe exchange programs: lowering the transmission of syringe-borne diseases and beyond. Public Health 1999;113(Suppl 1):67-74. 6703720
66. Higgs P, Aitken C, Cogger S, Papanastasiou C, Dietze P. Hepatitis C incidence in the Melbourne injecting drug user cohort study: 2009-2012. Drug and Alcohol Review 2012;31:33. 6703722
67. Jackson JB, Wei L, Liping F, Aramrattana A, Celentano DD, Walshe L, et al. Prevalence and seroincidence of hepatitis B and hepatitis C infection in high risk people who inject drugs in China and Thailand. Hepatitis Research and Treatment 2014;2014:296958. [DOI: 10.1155/2014/296958]6703724
68. Javanbakht M, Mirahmadizadeh A, Mashayekhi A. The long-term effectiveness of methadone maintenance treatment in prevention of hepatitis C virus among illicit drug users: a modeling study. Iranian Red Crescent Medical Journal 2014;16(2):e13484. [DOI: 10.5812/ircmj.13484]6703726
69. Judd A, Hickman M, Jones S, McDonald T, Parry JV, Stimson GV, et al. Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. BMJ 2005;330(7481):24-5. 6703728
70. Kwon JA, Iversen J, Maher L, Law MG, Wilson DP. The impact of needle and syringe programs on HIV and HCV transmissions in injecting drug users in Australia: a model-based analysis. Journal of Acquired Immune Deficiency Syndromes 2009;51(4):462-9. 6703730
71. Lai S, Liu W, Chen J, Yang J, Li Z-J, Li R-J, et al. Changes in HIV-1 incidence in heroin users in Guangxi Province, China. Journal of Acquired Immune Deficiency Syndromes 2001;26(4):365-70. 6703732
72. Larney S, Grebely J, Falster M, Swart A, Amin J, Degenhardt L, et al. Opioid substitution therapy is associated with increased detection of hepatitis C virus infection: a 15-year observational cohort study. Drug and Alcohol Dependence 2015;148:213-6. 6703734
73. Mansson AS, Moestrup T, Nordenfelt E, Widell A. Continued transmission of hepatitis B and C viruses, but no transmission of human immunodeficiency virus among intravenous drug users participating in a syringe/needle exchange program. Scandinavian Journal of Infectious Diseases 2000;32(3):253-8. 6703736
74. Mikolajczyk R, Prins M, Wiesing L, Kretzschmar M. Trajectories of injecting behaviour in the Amsterdam Cohort Study among drug users. European Journal of Epidemiology 2013;28:S13-4. 6703738
75. Moshkovich GF, Pikovskaia ED, Fedotova NV, Shilov DV, Kuznetsov AV, Moiseev AP. The prevention of HIV infection and other blood-contact diseases among intravenous narcotic users in Nizhniy Novgorod within the framework of the Harm Reduction program [Profilaktika VICh-infektsii i drugikh gemokontaktnykh zabolevanii sredi potrebitelei vnutrivennykh narkotikov Nizhnego Novgoroda v ramkakh programmy "Snizhenie vreda"]. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii 2000, (4):78-82. 6703740
76. Muga R, Sanvisens A, Bolao F, Tor J, Santesmases J, Pujol R, et al. Significant reductions of HIV prevalence but not of hepatitis C virus infections in injection drug users from metropolitan Barcelona: 1987-2001. Drug and Alcohol Dependence 2006;82:S29-33. 6703742
77. Nasir A, Todd CS, Stanekzai MR, Bautista CT, Botros BA, Scott PT, et al. Implications of hepatitis C viremia vs. antibody alone on transmission among male injecting drug users in three Afghan cities. International Journal of Infectious Diseases 2011;15(3):e201-5. 6703744
78. Page K, Hahn JA, Evans J, Shiboski S, Lum P, Delwart E, et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. Journal of Infectious Diseases 2009;200(8):1216-26. 6703746
79. Page K, Osburn W, Evans J, Hahn J, Cox A, Busch M. Controlling hepatitis C virus (HCV): reinfection and intercalation and clearance of viremia in highly exposed young injectors. Journal of Hepatology 2011;54:S463. 6703748
80. Page K, Osburn W, Evans J, Hahn JA, Lum P, Asher A, et al. Frequent longitudinal sampling of hepatitis C virus infection in injection drug users reveals intermittently detectable viremia and reinfection. Clinical Infectious Diseases 2013;56(3):405-13. 6703749
81. Palmateer N, Hutchinson S, McAllister G, Munro A, Cameron S, Goldberg D, et al. Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus (HCV) infection using cross-sectional survey data. Journal of Viral Hepatitis 2014;21(1):25-32. 6703751
82. Paquette C, Roy E, Petit G, Boivin J-F. Predictors of crack cocaine initiation among Montreal street youth: a first look at the phenomenon. Drug and Alcohol Dependence 2010;110(1-2):85-91. 6703753
83. Parrino MW. Drug Court Fact Sheet: methadone maintenance and other pharmacotherapeutic interventions in the treatment of opioid dependence. Journal of Maintenance in the Addictions 2003;2:85-93. 6703755
84. Pedrana A, Aitken C, Higgs P, Spelman T, Bowden S, Bharadwaj M, et al. High incidence of hepatitis C virus resolution and reinfection in a cohort of injecting drugs users. Drug and Alcohol Review 2009;28:A50-1. 6703757
85. Peles E, Schreiber S, Rados V, Adelson M. Low risk for hepatitis C seroconversion in methadone maintenance treatment. Journal of Addiction Medicine 2011;5(3):214-20. 6703759
86. Pollack HA. Cost-effectiveness of harm reduction in preventing hepatitis C among injection drug users. Medical Decision Making 2001;21(5):357-67. 6703761
87. Pratt Udeagu CCN, Paone D, Carter R J, Layton M C. Hepatitis C screening and management practices: a survey of drug treatment and syringe exchange programs in New York City. American Journal of Public Health 2002;92(8):1254-6. 6703763
88. Robotin MC, Copland J, Tallis G, Coleman D, Giele C, Carter L, et al. Surveillance for newly acquired hepatitis C in Australia. Journal of Gastroenterology and Hepatology 2004;19:283-8. 6703765
89. Rohrig S, Grob PJ. Infection with hepatitis viruses HAV, HBV and HCV as well as with AIDS virus HIV in drug addicts of the Zurich street scene--a prevalence study [Infektionen mit den Hepatitisviren HAV, HBV und HCV sowie mit dem Aidsvirus HIV bei Drogenabhangigen der Gassenszene Zurichs--eine Pravalenzstudie]. Schweizerische Medizinische Wochenschrift 1990;120(17):621-9. 6703767
90. Roux P, Michel L, Cohen J, Mora M, Morel A, Aubertin JF, et al. Methadone induction in primary care (ANRS-Methaville): a phase III randomized intervention trial. BMC Public Health 2012;12:488. 6703769
91. Roux P, Lions C, Michel L, Mora M, Daulouede J P, Marcellin F, et al. Factors associated with HCV risk practices in methadone-maintained patients: the importance of considering the couple in prevention interventions. Substance Abuse Treatment, Prevention, and Policy 2014;9:37. 6703771
92. Roy E, Boudreau J-F, Boivin J-F. Hepatitis C virus incidence among young street-involved IDUs in relation to injection experience. Drug and Alcohol Dependence 2009;102(1-3):158-61. 6703773
93. Roy E, Arruda N, Leclerc P, Haley N, Bruneau J, Boivin J-F. Injection of drug residue as a potential risk factor for HCV acquisition among Montreal young injection drug users. Drug and Alcohol Dependence 2012;126:246-50. 6703775
94. Ruan Y, Liang S, Zhu J, Li X, Pan SW, Liu Q, et al. Evaluation of harm reduction programs on seroincidence of HIV, hepatitis B and C, and syphilis among intravenous drug users in Southwest China. Sexually Transmitted Diseases 2013;40(4):323-8. 6703777
95. Samo RN, Altaf A, Agha A, Pasha O, Rozi S, Memon A, et al. High HIV incidence among persons who inject drugs in Pakistan: greater risk with needle sharing and injecting frequently among the homeless. PLOS ONE 2013;8:e81715. [DOI: 10.1371/journal.pone.0081715]6703779
96. Sanders-Buell E, Rutvisuttinunt W, Todd CS, Nasir A, Bradfield A, Lei E, et al. Hepatitis C genotype distribution and homology among geographically disparate injecting drug users in Afghanistan. Journal of Medical Virology 2013;85(7):1170-9. 6703781
97. Seal KH, Monto A, Dove L, Vittinghoff E, Shen H, Tracy D, et al. Determinants of hepatitis C viral RNA levels among a cohort of injection drug users with and without human immunodeficiency virus coinfection. Hepatology 2004;40:403A. 6703783
98. Selvey LA, Denton M, Plant AJ. Incidence and prevalence of hepatitis C among clients of a Brisbane methadone clinic: Factors influencing hepatitis C serostatus. Australian and New Zealand Journal of Public Health 1997;21(1):102-4. 6703784
99. Selvey LA, Denton M, Plant AJ. Incidence and prevalence of hepatitis C among clients of a Brisbane methadone clinic: Factors influencing hepatitis C serostatus. Australia and New Zealand Journal of Public Health 1997;21(1):102-104. 6703786
100. Sendi P, Hoffmann M, Bucher HC, Erb P, Haller P, Gyr N, et al. Intravenous opiate maintenance in a cohort of injecting drug addicts. Drug and Alcohol Dependence 2003;69(2):183-8. 6703788
101. Shannon K, Kerr T, Marshall B, Li K, Zhang R, Strathdee SA, et al. Survival sex work involvement as a primary risk factor for hepatitis C virus acquisition in drug-using youths in a Canadian setting. Archives of Pediatrics and Adolescent Medicine 2010;164(1):61-5. 6703790
102. Shi J, Zhao LY, Epstein DH, Zhao CZ, Shuai YL, Yan B, et al. The effect of methadone maintenance on illicit opioid use, human immunodeficiency virus and hepatitis C virus infection, health status, employment, and criminal activity among heroin abusers during 6 months of treatment in China. Journal of Addiction Medicine 2007;1(4):186-90. 6703792
103. Solomon SS, Celentano DD, Srikrishnan AK, Vasudevan CK, Murugavel KG, Iqbal SH, et al. Low incidences of human immunodeficiency virus and hepatitis C virus infection and declining risk behaviors in a cohort of injection drug users in Chennai, India. American Journal of Epidemiology 2010;172(11):1259-67. 6703794
104. Spencer JD, Latt N, Beeby PJ, Collins E, Saunders JB, McCaughan GW, et al. Transmission of hepatitis C virus to infants of human immunodeficiency virus-negative intravenous drug-using mothers: rate of infection and assessment of risk factors for transmission. Journal of Viral Hepatitis 1997;4(6):395-409. 6703796
105. Steffen T, Blattler R, Gutzwiller F, Zwahlen M. HIV and hepatitis virus infections among injecting drug users in a medically controlled heroin prescription programme. European Journal of Public Health 2001;11(4):425-30. 6703798
106. Stein MD, Herman DS, Anderson BJ. A trial to reduce hepatitis C seroincidence in drug users. Journal of Addictive Diseases 2009;28(4):389-98. 6703800
107. Stephens BP, Tait J, Dillon JF. Is it worth testing unstable drug users for hepatitis C?. Hepatology 2011;54:844A. 6703802
108. Stephens BP, Tait J, Evans M, Dillon JF. The natural history of the acquisition of HCV in chaotic PWID. Hepatology 2013;58:1103A. 6703804
109. Strathdee SA, Patrick DM, Currie SL, Cornelisse PGA, Rekart ML, Montaner JSG, et al. Needle exchange is not enough: Lessons from the Vancouver injecting drug use study. AIDS 1997;11:F59-65. 6703806
110. Sullivan LE, Chawarski M, O'Connor PG, Schottenfeld RS, Fiellin DA. The practice of office-based buprenorphine treatment of opioid dependence: Is it associated with new patients entering into treatment?. Drug and Alcohol Dependence 2005;79(1):113-6. 6703808
111. Sylvestre D. Hepatitis C treatment in drug users: perception versus evidence. European Journal of Gastroenterology & Hepatology 2006;18(2):129-30. 6703810
112. Tait JM, Stephens BP, McIntyre P, Evans M, Dillon JF. Dry blood spot testing for hepatitis C in people who injected drugs: reaching the populations other tests cannot reach. Journal of Hepatology 2013;58:S204. 6703812
113. Tait J, Stephens BP, Evans M, Cleary S, Dillon JF. People who inject drugs (PWID): difficult to get into services, easy to cure. Hepatology 2013;58:1102A-3A. 6703814
114. Todd CS, Nasir A, Stanekzai MR, Fiekert K, Sipsma HL, Vlahov D, et al. Hepatitis C and HIV incidence and harm reduction program use in a conflict setting: an observational cohort of injecting drug users in Kabul, Afghanistan. Harm Reduction Journal 2015;12(1):Article Number: 22. [DOI: 10.1186/s12954-015-0056-z]6703816
115. Tracy D, Hahn JA, Fuller Lewis C, Evans J, Briceno A, Morris MD, et al. Higher risk of incident hepatitis C virus among young women who inject drugs compared with young men in association with sexual relationships: a prospective analysis from the UFO Study cohort. BMJ Open 2014;4(5):e004988. [DOI: 10.1136/bmjopen-2014-004988]6703818
116. Tsirogianni E, Kokkonis G, Tziokgas K, Tsekoura P, Stafilidou M, Sotiriadou K, et al. Incidence of new HCV infection or reinfection after successful anti-HCV therapy among people who inject drugs attending a substitution treatment programme in northern Greece. Suchtmedizin in Forschung und Praxis 2013;15(4):260. 6703820
117. Tsui JI, Vittinghoff E, Hahn JA, Evans JL, Davidson PJ, Page K. Risk behaviors after hepatitis C virus seroconversion in young injection drug users in San Francisco. Drug and Alcohol Dependence 2009;105(1-2):160-3. 6703822
118. Valdez A, Neaigus A, Kaplan C, Cepeda A. High rates of transitions to injecting drug use among Mexican American non-injecting heroin users in San Antonio, Texas (never and former injectors). Drug and Alcohol Dependence 2011;114(2-3):233-6. 6703824
119. Van Ameijden EJ, Van den Hoek JA, Mientjes GH, Coutinho RA. A longitudinal study on the incidence and transmission patterns of HIV, HBV and HCV infection among drug users in Amsterdam. European Journal of Epidemiology 1993;9(3):255-62. 6703826
120. Van den Hoek JAR, Van Haastrecht HJA, Goudsmit J, De Wolf F, Coutinho RA. Prevalence, incidence, and risk factors of hepatitis C virus infection among drug users in Amsterdam. Journal of Infectious Diseases 1990;162(4):823-6. 6703828
121. Van de Laar TJW, Molenkamp R, Van den Berg C, Schinkel J, Beld MGHM, Prins M, et al. Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam. Journal of Hepatology 2009;51(4):667-74. 6703830
122. Van De Laar TJ, Rondy M, Bruisten SM, Prins M, van Ballegooijen M. Long term follow-up of injecting drug users suggests protective immunity against HCV reinfection and superinfection with a similar genotype. Journal of Hepatology 2010;52:S262-3. 6703832
123. Van Santen DK, De Vos AS, Van Der Helm JJ, Grady BPX, Kretzschmar MEE, Stolte IG, et al. Temporal trends in mortality rates among drug users in Amsterdam compared to the general Dutch population differ by hepatitis C and HIV (co)infection status. Suchtmedizin in Forschung und Praxis 2013;15(4):235. 6703834
124. Villano SA, Vlahov D, Nelson KE, Lyles CM, Cohn S, Thomas DL. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. Journal of Clinical Microbiology 1997;35(12):3274-7. 6703836
125. Wand H, Spiegelman D, Law M, Jalaludin B, Kaldor J, Maher L. Estimating population attributable risk for hepatitis C seroconversion in injecting drug users in Australia: Implications for prevention policy and planning. Addiction 2009;104(12):2049-56. 6703838
126. Wang L, Wei X, Wang X, Li J, Li H, Jia W. Long-term effects of methadone maintenance treatment with different psychosocial intervention models. PLOS ONE 2014;9(2):e87931. [DOI: 10.1371/journal.pone.0087931]6703840
127. Widell A, Alanko M, Flamholc L, Jacobssen H, Molnegren V, Bjorkman P. Continued heavy transmission of HCV in a needle exchange program that is associated with minimal transmission of HIV. A nine year longitudinal cohort study. Journal of Hepatology 2009;50:S161. 6703842
128. Winkelstein ER, Edlin BR, Szott K, Shu MA, McKnight C, DesJarlais DC, et al. The SWAN Project: integrating research and service with a cohort of young people who use drugs at risk for hepatitis C in New York City. Suchtmedizin in Forschung und Praxis 2013;15:238. 6703844
129. Woody GE, Poole SA, Subramaniam G, Dugosh K, Bogenschutz M, Abbott P, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA 2008;300(17):2003-11. 6703846
130. Yang J, Oviedo-Joekes E, Christian KWM, Li K, Louie M, Schechter M, et al. The Cedar Project: methadone maintenance treatment among young Aboriginal people who use opioids in two Canadian cities. Drug and Alcohol Review 2011;30(6):645-51. 6703848
131. Yen Y F, Yen M Y, Su L W, Li L H, Chuang P, Jiang X R, et al. Prevalences and associated risk factors of HCV/HIV co-infection and HCV mono-infection among injecting drug users in a methadone maintenance treatment program in Taipei, Taiwan. BMC Public Health 2012;12:1066. [DOI: 10.1186/1471-2458-12-1066]6703850
132. Zhao M, Wang QY, Lu GH, Xu P, Xu H, McCoy CB. Risk behaviors and HIV/AIDS prevention education among IDUs in drug treatment in Shanghai. Urban Health 2005;82:iv84-91. 6703852
133. Zhou W, Wang X, Zhou S, Xie N, Liu P, Luo L, et al. Hepatitis C seroconversion in methadone maintenance treatment programs in Wuhan, China. Addiction 2015;110(5):796-802. 6703854
134. Zou X, Ling L, Zhang L. Trends and risk factors for HIV, HCV and syphilis seroconversion among drug users in a methadone maintenance treatment programme in China: a 7-year retrospective cohort study. BMJ Open 2015;5(8):e008162. [DOI: 10.1136/bmjopen-2015-008162]6703856
135. Zunt J, Tapia K, Thiede H, Lee R, Hagan H. HTLV-2 infection in injection drug users in King County, Washington. Scandinavian Journal of Infectious Diseases 2006;38(8):654-63. 6703858
136. Bruneau J, Asward DJ, Zang G, Roy E. Effect of combined harm reduction strategies on HCV incidence among people who inject drugs in Montreal, Canada. Journal of Hepatology 2016;64(2):S462. 6703860
137. Chun H, Li Z, Yuhua R, Yu Z, Zongliang F, Lu Y, et al. On the impact of community-based methadone maintenance treatment among drug addicts. Journal of Preventive Medicine Information 2006;22:251-5. 6703862
138. Duan S, Han J, Tang RH, Yang YC, Xiang LF, Ye RH, et al. Study on the incidence and risk factors of HCV infection among heroin addicts who were on methadone maintenance treatment in Dehong prefecture, Yunnan province. Zhonghua Liuxingbing Xue Zazhi [Chinese Journal of Epidemiology] 2013;34(6):552-6. 6703864
139. He YX, Ruan YH, Teng T, Hao QN, Qin GM, Wu JL, et al. Community-based survey of drug use and sexual behavior among female injection drug users. Zhongguo Aizibing Xingbing [Chinese Journal of AIDS & STD] 2003;9:343-6. 6703866
140. He YX, Teng T, Ruan YH, Zhou F, Liu SZ, Liu G, et al. A survey of drug abuse and behaviors among injection drug users in Liangshan of Sichuan Province. Zhongguo Yaowu Lanyong Fangzhi Zazhi [Chinese Journal of Drug Abuse Prevention andTreatment] 2004;10:80-3. 6703868
141. Mathei C, Bourgeois S, Blach S, Brixko C, Mulkay KP, Razavi H, et al. Mitigating the burden of hepatitis C virus among people who inject drugs in Belgium. Acta Gastro-Enterologica Belgica 2016;79(2):227-32. 6703870
142. O'Keefe D, Scott N, Aitken C, Dietze P. Individual-level needle and syringe coverage in Melbourne, Australia: a longitudinal, descriptive analysis. BMC Health Service Research 2016;16(1):411. [DOI: 10.1186/s12913-016-1668-z.]6703872
143. Ray Saraswati L, Saran A, Sebastian MP, Sharma V, Madan I, Thior I, et al. HIV, Hepatitis B and C among people who inject drugs: high prevalence of HIV and Hepatitis C RNA positive infections observed in Delhi, India. BMC Public Health 2015;15:726. [DOI: 10.1186/s12889-015-2003-z]6703874
144. Siedentopf J-P, Nagel M, Buscher U. Possibilities of drug addiction treatment during pregnancy [Moglichkeiten der suchttherapie in der schwangerschaft]. Suchtmedizin in Forschung und Praxis 2002;4:162-3. 6703876
145. Wada K. HCV infection among narcotics/methamphetamine abusers. Nippon Rinsho 2004;62(Suppl 7):326-9. 6703878
146. Amato L, Davoli M, Minozzi S, Ferroni E, Ali R, Ferri M. Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database of Systematic Reviews 2013, Issue 2. [DOI: 10.1002/14651858.CD003409.pub4]
147. Aspinall EJ, Nambiar D, Goldberg DJ, Hickman M, Weir A, Van Velzen E, et al. Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. International Journal of Epidemiology 2014;43(1):235-48.
148. Bluthenthal RN, Anderson R, Flynn NM, Kral AH. Higher syringe coverage is associated with lower odds of HIV risk and does not increase unsafe syringe disposal among syringe exchange program clients. Drug and Alcohol Dependence 2007;89(2-3):214-22.
149. Bourgois P, Prince B, Moss A. The everyday violence of hepatitis C among young women who inject drugs in San Francisco. Human Organization 2004;63(3):253-64.
150. Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet 2010;376(9737):285-301.
151. Esmaeili A, Mirzazadeh A, Carter GM, Esmaeili, Hajarizadeh B, Sack HS, et al. Higher incidence of HCV in females compared to males who inject drugs: a systematic review and meta-analysis. Journal of Viral Hepatitis 2016;24(2):117-27.
152. Faggiano F, Vigna-Taglianti F, Versino E, Lemma P. Methadone maintenance at different dosages for opioid dependence. Cochrane Database of Systematic Reviews 2003, Issue 3. [DOI: 10.1002/14651858.CD002208]
153. Gibson DR, Flynn NM, McCarthy JJ. Effectiveness of methadone treatment in reducing HIV risk behavior and HIV seroconversion among injecting drug users. Aids 1999;13(14):1807-18.
154. Gibson DR, Flynn NM, Perales D. Effectiveness of syringe exchange programs in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS 2001;15(11):1329-41.
155. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. Journal of Hepatology 2014;61(1 Suppl):S45-57.
156. Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database of Systematic Reviews 2011, Issue 8. [DOI: 10.1002/14651858.CD004145.pub4]
157. The GRADE working group. Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490-4.
158. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6.
159. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64:383-94.
160. Hagan H, Pouget ER, Des Jarlais DC. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. Journal of Infectious Diseases 2011;204(1):74-83.
161. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane-handbook.org, 2011.
162. Hope VD, Hickman M, Ngui SL, Jones S, Telfer M, Bizzarri M, et al. Incidence of HCV infection in PWID as measured via repeat testing such as detection of HCV RNA positive among HCV antibody negative results or antibody avidity. Journal of Viral Hepatitis 2010;18:262-70.
163. Iversen J, Page K, Madden A, Maher L. HIV, HCV and health-related harms among women who inject drugs: Implications for prevention and treatment. Journal of Acquired Immune Deficiency Syndromes 2015;69(Suppl 2):S176-S181.
164. Jones L, Pickering L, Sumnall H, Mcveigh J, Bellis MA. A review of the effectiveness and cost-effectiveness of needle and syringe programmes for injecting drug users. Liverpool: Centre for Public Health, Liverpool John Moores University, 2008.
165. Kaplan EH, Heimer R. A model-based estimate of HIV infectivity via needle sharing. Journal of Acquired Immune Deficiency Syndromes 1992;5(11):1116-8.
166. MacArthur GJ, Minozzi S, Martin N, Vickerman P, Deren S, Bruneau J, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ 2012;345:e5945.
167. Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008;372(9651):1733-45.
168. Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 2010;375(9719):1014-28.
169. Miller CL, Wood E, Spittal PM, Li K, Frankish JC, Braitstein P, et al. The future face of coinfection: prevalence and incidence of HIV and hepatitis C virus coinfection among young injection drug users. Journal of Acquired Immune Deficiency Syndromes 2004;36(2):743-9.
170. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57(4):1333-42.
171. Palmateer N, Kimber J, Hickman M, Hutchinson S, Rhodes T, Goldberg D. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. Addiction 2010;105(5):844-59.
172. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. Journal of Hepatology 2006;45(4):529-38.
173. Platt L, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infectious Diseases 2016;16(7):797-808.
174. Platt L, Reed J, Minozzi S, Vickerman P, Hagan H, French C, Jordan A, Degenhardt L, Hope V, Hutchinson S, Maher L, Palmateer N, Taylor A, Hickman M. Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs. Cochrane Database of Systematic Reviews 12 Januray 2016;1.
175. Pouget ER, Hagan H, Des Jarlais DC. Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment. Addiction 2012;107(6):1057-65.
176. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
177. Schünemann HJ, Jaeschke R, Cook D, Bria W, El-Solh A, Ernst A, et al. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. American Journal of Respiratory and Critical Care Medicine 2006;174(5):605-14.
178. Sterne J, Higgins J, Reeves B. Extending the risk of bias tool to allow for assessment of non-randomised studies, clust-randomised trials and cross-over trials:a Cochrane methods innovation fund project (Workshop), 21st Cochrane Colloquium Abstract Book. The Cochrane Collaboration, 2013.
179. Strathdee SA, Hallett TB, Bobrova N, Rhodes T, Booth R, Abdool R, et al. HIV and risk environment for injecting drug users: the past, present, and future. Lancet 2010;376(9737):268-84.
180. Tilson H, Aramrattana A, Bozzette SA. Preventing HIV Infection among Injecting Drug Users in High-risk Countries: An Assessment of the Evidence. Washington, DC: Institute of Medicine, 2007.
181. Turner KM, Hutchinson S, Vickerman P, Hope V, Craine N, Palmateer N, et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction 2011;106(11):1978-88.
182. UNAIDS. Global Statistics. Fact Sheet. UNAIDS, 2014.
183. Vickerman P, Martin N, Turner K, Hickman M. Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. Addiction 2012;107(11):1984-95.
184. Vickerman P, Platt L, Jolley E, Rhodes T, Kazatchkine MD, Latypov A. Controlling HIV among people who inject drugs in Eastern Europe and Central Asia: insights from modeling. International Journal on Drug Policy 2014;25(6):1163-73.
185. Vorma H, Sokero P, Aaltonen M, Turtiainen S, Hughes LA, Savolainen J. Participation in opioid substitution treatment reduces the rate of criminal convictions: evidence from a community study. Addictive Behaviors 2013;38(7):2316-6.
186. World Health Organization, United Nations Office on Drugs and Crime & UNAIDS. Substitution maintenance therapy in the management of opiod dependence and HIV/AIDS prevention: position paper. World Health Organization, 2004.
187. Wiessing L, Likatavicius G, Klempova D, Hedrich D, Nardone A, Griffiths P. Associations between availability and coverage of HIV-prevention measures and subsequent incidence of diagnosed HIV infection among injection drug users. American Journal of Public Health 2009;99(6):1049-52.
188. Wodak A, Cooney A. Effectiveness of sterile needle and syringe programming in reducing HIV/AIDS among injecting drug users. Evidence for Action Technical Papers. Geneva: World Health Organization, 2004.
189. Wood E, Lloyd-Smith E, Li K, Strathdee S, Tyndall M, Montaner J, et al. Frequent needle exchange use and HIV incidence in Vancouver, Canada. American Journal of Medicine 2007;120(2):172-9.
190. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 1998;280(19):1960-1.
191. Platt L, Reed J, Minozzi S, Vickerman P, Hagan H, French C, et al. Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs. Cochrane Database of Systematic Reviews 12 January, Issue 1. [DOI: 10.1002/14651858; CD012021.]